APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diabetic Neuropathic Pain Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Diabetic Neuropathic Pain Drug Market Outlook and Growth Opportunities 2026

26 December 2025209 pages

Choose your research edition.

Industry ResearchDiabetic Neuropathic Pain Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetic Neuropathic Pain Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Diabetic Neuropathic Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetic Neuropathic Pain Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetic Neuropathic Pain Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Diabetic Neuropathic Pain Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Diabetic Neuropathic Pain Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Diabetic Neuropathic Pain Drug market include Eli Lilly and Company, Astellas Pharma Inc., AstraZeneca Plc, Theravasc, Inc., Sphaera Pharma Pvt. Ltd., Relmada Therapeutics, Inc., RAPID Pharmaceuticals AG, Pharmaleads and Novaremed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Diabetic Neuropathic Pain Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diabetic Neuropathic Pain Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diabetic Neuropathic Pain Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diabetic Neuropathic Pain Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Diabetic Neuropathic Pain Drug Segment by Company

Eli Lilly and Company

Astellas Pharma Inc.

AstraZeneca Plc

Theravasc, Inc.

Sphaera Pharma Pvt. Ltd.

Relmada Therapeutics, Inc.

RAPID Pharmaceuticals AG

Pharmaleads

Novaremed

Mertiva AB

Lohocla Research Corporation

Laboratorios Del Dr. Esteve S.A.

Immune Pharmaceuticals Inc.

Hydra Biosciences, Inc.

Glenmark Pharmaceuticals Ltd.

Dong-A Socio Group

Daiichi Sankyo Company, Limited

Boehringer Ingelheim GmbH

BioDelivery Sciences International, Inc.

Diabetic Neuropathic Pain Drug Segment by Type

AZD-5213

E-52862

GERPOOI

GRC-17536

Filgrastim

Duloxetine Hydrochloride DR

Clonidine Hydrochloride

Others

Diabetic Neuropathic Pain Drug Segment by Application

Clinic

Hospital

Others

Diabetic Neuropathic Pain Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Diabetic Neuropathic Pain Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Diabetic Neuropathic Pain Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Diabetic Neuropathic Pain Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Diabetic Neuropathic Pain Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Neuropathic Pain Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetic Neuropathic Pain Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Neuropathic Pain Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diabetic Neuropathic Pain Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diabetic Neuropathic Pain Drug industry.

Chapter 3: Detailed analysis of Diabetic Neuropathic Pain Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Diabetic Neuropathic Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Diabetic Neuropathic Pain Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Diabetic Neuropathic Pain Drug Industry Trends Table 2. Diabetic Neuropathic Pain Drug Industry Drivers Table 3. Diabetic Neuropathic Pain Drug Industry Opportunities and Challenges Table 4. Diabetic Neuropathic Pain Drug Industry Restraints Table 5. Global Diabetic Neuropathic Pain Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Diabetic Neuropathic Pain Drug Revenue Share by Company (2021-2026) Table 7. Global Diabetic Neuropathic Pain Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Diabetic Neuropathic Pain Drug Sales Volume Share by Company (2021-2026) Table 9. Global Diabetic Neuropathic Pain Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Diabetic Neuropathic Pain Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Diabetic Neuropathic Pain Drug Key Company Manufacturing Base & Headquarters Table 12. Global Diabetic Neuropathic Pain Drug Company, Product Type & Application Table 13. Global Diabetic Neuropathic Pain Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Diabetic Neuropathic Pain Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of AZD-5213 Table 18. Significant Companies of E-52862 Table 19. Significant Companies of GERPOOI Table 20. Significant Companies of GRC-17536 Table 21. Significant Companies of Filgrastim Table 22. Significant Companies of Duloxetine Hydrochloride DR Table 23. Significant Companies of Clonidine Hydrochloride Table 24. Significant Companies of Others Table 25. Global Diabetic Neuropathic Pain Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Diabetic Neuropathic Pain Drug Sales Volume by Type (2021-2026) & (W Units) Table 27. Global Diabetic Neuropathic Pain Drug Sales Volume by Type (2027-2032) & (W Units) Table 28. Global Diabetic Neuropathic Pain Drug Sales Volume Share by Type (2021-2026) Table 29. Global Diabetic Neuropathic Pain Drug Sales Volume Share by Type (2027-2032) Table 30. Global Diabetic Neuropathic Pain Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Diabetic Neuropathic Pain Drug Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Diabetic Neuropathic Pain Drug Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Diabetic Neuropathic Pain Drug Sales Value Share by Type (2021-2026) Table 34. Global Diabetic Neuropathic Pain Drug Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Clinic Table 36. Significant Companies of Hospital Table 37. Significant Companies of Others Table 38. Global Diabetic Neuropathic Pain Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Diabetic Neuropathic Pain Drug Sales Volume by Application (2021-2026) & (W Units) Table 40. Global Diabetic Neuropathic Pain Drug Sales Volume by Application (2027-2032) & (W Units) Table 41. Global Diabetic Neuropathic Pain Drug Sales Volume Share by Application (2021-2026) Table 42. Global Diabetic Neuropathic Pain Drug Sales Volume Share by Application (2027-2032) Table 43. Global Diabetic Neuropathic Pain Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Diabetic Neuropathic Pain Drug Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Diabetic Neuropathic Pain Drug Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Diabetic Neuropathic Pain Drug Sales Value Share by Application (2021-2026) Table 47. Global Diabetic Neuropathic Pain Drug Sales Value Share by Application (2027-2032) Table 48. Global Diabetic Neuropathic Pain Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 49. Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2026) & (W Units) Table 50. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2021-2026) Table 51. Global Diabetic Neuropathic Pain Drug Sales by Region (2027-2032) & (W Units) Table 52. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2027-2032) Table 53. Global Diabetic Neuropathic Pain Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Diabetic Neuropathic Pain Drug Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Diabetic Neuropathic Pain Drug Sales Value Share by Region (2021-2026) Table 56. Global Diabetic Neuropathic Pain Drug Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Diabetic Neuropathic Pain Drug Sales Value Share by Region (2027-2032) Table 58. Global Diabetic Neuropathic Pain Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Diabetic Neuropathic Pain Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Diabetic Neuropathic Pain Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 61. Global Diabetic Neuropathic Pain Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 63. Global Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2026) Table 64. Global Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 65. Global Diabetic Neuropathic Pain Drug Sales Market Share by Country (2027-2032) Table 66. Global Diabetic Neuropathic Pain Drug Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Diabetic Neuropathic Pain Drug Sales Value Market Share by Country (2021-2026) Table 68. Global Diabetic Neuropathic Pain Drug Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Diabetic Neuropathic Pain Drug Sales Value Market Share by Country (2027-2032) Table 70. Eli Lilly and Company Company Information Table 71. Eli Lilly and Company Business Overview Table 72. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio Table 74. Eli Lilly and Company Recent Development Table 75. Astellas Pharma Inc. Company Information Table 76. Astellas Pharma Inc. Business Overview Table 77. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 79. Astellas Pharma Inc. Recent Development Table 80. AstraZeneca Plc Company Information Table 81. AstraZeneca Plc Business Overview Table 82. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio Table 84. AstraZeneca Plc Recent Development Table 85. Theravasc, Inc. Company Information Table 86. Theravasc, Inc. Business Overview Table 87. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 89. Theravasc, Inc. Recent Development Table 90. Sphaera Pharma Pvt. Ltd. Company Information Table 91. Sphaera Pharma Pvt. Ltd. Business Overview Table 92. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio Table 94. Sphaera Pharma Pvt. Ltd. Recent Development Table 95. Relmada Therapeutics, Inc. Company Information Table 96. Relmada Therapeutics, Inc. Business Overview Table 97. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 99. Relmada Therapeutics, Inc. Recent Development Table 100. RAPID Pharmaceuticals AG Company Information Table 101. RAPID Pharmaceuticals AG Business Overview Table 102. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio Table 104. RAPID Pharmaceuticals AG Recent Development Table 105. Pharmaleads Company Information Table 106. Pharmaleads Business Overview Table 107. Pharmaleads Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio Table 109. Pharmaleads Recent Development Table 110. Novaremed Company Information Table 111. Novaremed Business Overview Table 112. Novaremed Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Novaremed Diabetic Neuropathic Pain Drug Product Portfolio Table 114. Novaremed Recent Development Table 115. Mertiva AB Company Information Table 116. Mertiva AB Business Overview Table 117. Mertiva AB Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio Table 119. Mertiva AB Recent Development Table 120. Lohocla Research Corporation Company Information Table 121. Lohocla Research Corporation Business Overview Table 122. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio Table 124. Lohocla Research Corporation Recent Development Table 125. Laboratorios Del Dr. Esteve S.A. Company Information Table 126. Laboratorios Del Dr. Esteve S.A. Business Overview Table 127. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio Table 129. Laboratorios Del Dr. Esteve S.A. Recent Development Table 130. Immune Pharmaceuticals Inc. Company Information Table 131. Immune Pharmaceuticals Inc. Business Overview Table 132. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 134. Immune Pharmaceuticals Inc. Recent Development Table 135. Hydra Biosciences, Inc. Company Information Table 136. Hydra Biosciences, Inc. Business Overview Table 137. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 139. Hydra Biosciences, Inc. Recent Development Table 140. Glenmark Pharmaceuticals Ltd. Company Information Table 141. Glenmark Pharmaceuticals Ltd. Business Overview Table 142. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio Table 144. Glenmark Pharmaceuticals Ltd. Recent Development Table 145. Dong-A Socio Group Company Information Table 146. Dong-A Socio Group Business Overview Table 147. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio Table 149. Dong-A Socio Group Recent Development Table 150. Daiichi Sankyo Company, Limited Company Information Table 151. Daiichi Sankyo Company, Limited Business Overview Table 152. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio Table 154. Daiichi Sankyo Company, Limited Recent Development Table 155. Boehringer Ingelheim GmbH Company Information Table 156. Boehringer Ingelheim GmbH Business Overview Table 157. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio Table 159. Boehringer Ingelheim GmbH Recent Development Table 160. BioDelivery Sciences International, Inc. Company Information Table 161. BioDelivery Sciences International, Inc. Business Overview Table 162. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 164. BioDelivery Sciences International, Inc. Recent Development Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. Diabetic Neuropathic Pain Drug Distributors List Table 168. Diabetic Neuropathic Pain Drug Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Diabetic Neuropathic Pain Drug Product Image Figure 2. Global Diabetic Neuropathic Pain Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetic Neuropathic Pain Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Diabetic Neuropathic Pain Drug Sales (2021-2032) & (W Units) Figure 5. Global Diabetic Neuropathic Pain Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Diabetic Neuropathic Pain Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. AZD-5213 Image Figure 10. E-52862 Image Figure 11. GERPOOI Image Figure 12. GRC-17536 Image Figure 13. Filgrastim Image Figure 14. Duloxetine Hydrochloride DR Image Figure 15. Clonidine Hydrochloride Image Figure 16. Others Image Figure 17. Global Diabetic Neuropathic Pain Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Diabetic Neuropathic Pain Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Diabetic Neuropathic Pain Drug Sales Volume Share by Type (2021-2032) Figure 20. Global Diabetic Neuropathic Pain Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Diabetic Neuropathic Pain Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Diabetic Neuropathic Pain Drug Sales Value Share by Type (2021-2032) Figure 23. Clinic Image Figure 24. Hospital Image Figure 25. Others Image Figure 26. Global Diabetic Neuropathic Pain Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Diabetic Neuropathic Pain Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Diabetic Neuropathic Pain Drug Sales Volume Share by Application (2021-2032) Figure 29. Global Diabetic Neuropathic Pain Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Diabetic Neuropathic Pain Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Diabetic Neuropathic Pain Drug Sales Value Share by Application (2021-2032) Figure 32. Global Diabetic Neuropathic Pain Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 33. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Diabetic Neuropathic Pain Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Diabetic Neuropathic Pain Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Diabetic Neuropathic Pain Drug Sales Value (2021-2032) & (US$ Million) Figure 37. North America Diabetic Neuropathic Pain Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Diabetic Neuropathic Pain Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Diabetic Neuropathic Pain Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Diabetic Neuropathic Pain Drug Sales Value (2021-2032) & (US$ Million) Figure 43. South America Diabetic Neuropathic Pain Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Diabetic Neuropathic Pain Drug Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Diabetic Neuropathic Pain Drug Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • AZD-5213
  • E-52862
  • GERPOOI
  • GRC-17536
  • Filgrastim
  • Duloxetine Hydrochloride DR
  • Clonidine Hydrochloride
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Theravasc, Inc.
  • Sphaera Pharma Pvt. Ltd.
  • Relmada Therapeutics, Inc.
  • RAPID Pharmaceuticals AG
  • Pharmaleads
  • Novaremed
  • Mertiva AB
  • Lohocla Research Corporation
  • Laboratorios Del Dr. Esteve S.A.
  • Immune Pharmaceuticals Inc.
  • Hydra Biosciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Dong-A Socio Group
  • Daiichi Sankyo Company, Limited
  • Boehringer Ingelheim GmbH
  • BioDelivery Sciences International, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Diabetic Neuropathic Pain Drug Sales Value (2021-2032)
  4. 1.2.2 Global Diabetic Neuropathic Pain Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Diabetic Neuropathic Pain Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Diabetic Neuropathic Pain Drug Market Dynamics
  1. 2.1 Diabetic Neuropathic Pain Drug Industry Trends
  2. 2.2 Diabetic Neuropathic Pain Drug Industry Drivers
  3. 2.3 Diabetic Neuropathic Pain Drug Industry Opportunities and Challenges
  4. 2.4 Diabetic Neuropathic Pain Drug Industry Restraints
3 Diabetic Neuropathic Pain Drug Market by Company
  1. 3.1 Global Diabetic Neuropathic Pain Drug Company Revenue Ranking in 2025
  2. 3.2 Global Diabetic Neuropathic Pain Drug Revenue by Company (2021-2026)
  3. 3.3 Global Diabetic Neuropathic Pain Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Diabetic Neuropathic Pain Drug Average Price by Company (2021-2026)
  5. 3.5 Global Diabetic Neuropathic Pain Drug Company Ranking (2024-2026)
  6. 3.6 Global Diabetic Neuropathic Pain Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Diabetic Neuropathic Pain Drug Company Product Type and Application
  8. 3.8 Global Diabetic Neuropathic Pain Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Diabetic Neuropathic Pain Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Diabetic Neuropathic Pain Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Diabetic Neuropathic Pain Drug Market by Type
  1. 4.1 Diabetic Neuropathic Pain Drug Type Introduction
  2. 4.1.1 AZD-5213
  3. 4.1.2 E-52862
  4. 4.1.3 GERPOOI
  5. 4.1.4 GRC-17536
  6. 4.1.5 Filgrastim
  7. 4.1.6 Duloxetine Hydrochloride DR
  8. 4.1.7 Clonidine Hydrochloride
  9. 4.1.8 Others
  10. 4.2 Global Diabetic Neuropathic Pain Drug Sales Volume by Type
  11. 4.2.1 Global Diabetic Neuropathic Pain Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Diabetic Neuropathic Pain Drug Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Diabetic Neuropathic Pain Drug Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Diabetic Neuropathic Pain Drug Sales Value by Type
  15. 4.3.1 Global Diabetic Neuropathic Pain Drug Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Diabetic Neuropathic Pain Drug Sales Value by Type (2021-2032)
  17. 4.3.3 Global Diabetic Neuropathic Pain Drug Sales Value Share by Type (2021-2032)
5 Diabetic Neuropathic Pain Drug Market by Application
  1. 5.1 Diabetic Neuropathic Pain Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Diabetic Neuropathic Pain Drug Sales Volume by Application
  6. 5.2.1 Global Diabetic Neuropathic Pain Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diabetic Neuropathic Pain Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Diabetic Neuropathic Pain Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Diabetic Neuropathic Pain Drug Sales Value by Application
  10. 5.3.1 Global Diabetic Neuropathic Pain Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Diabetic Neuropathic Pain Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Diabetic Neuropathic Pain Drug Sales Value Share by Application (2021-2032)
6 Diabetic Neuropathic Pain Drug Regional Sales and Value Analysis
  1. 6.1 Global Diabetic Neuropathic Pain Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Diabetic Neuropathic Pain Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Diabetic Neuropathic Pain Drug Sales by Region (2027-2032)
  5. 6.3 Global Diabetic Neuropathic Pain Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Diabetic Neuropathic Pain Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Diabetic Neuropathic Pain Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Diabetic Neuropathic Pain Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Diabetic Neuropathic Pain Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Diabetic Neuropathic Pain Drug Sales Value (2021-2032)
  12. 6.6.2 North America Diabetic Neuropathic Pain Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Diabetic Neuropathic Pain Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Diabetic Neuropathic Pain Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Diabetic Neuropathic Pain Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Diabetic Neuropathic Pain Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Diabetic Neuropathic Pain Drug Sales Value (2021-2032)
  21. 6.9.2 South America Diabetic Neuropathic Pain Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Diabetic Neuropathic Pain Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Diabetic Neuropathic Pain Drug Sales Value Share by Country, 2025 VS 2032
7 Diabetic Neuropathic Pain Drug Country-level Sales and Value Analysis
  1. 7.1 Global Diabetic Neuropathic Pain Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Diabetic Neuropathic Pain Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Diabetic Neuropathic Pain Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Diabetic Neuropathic Pain Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Diabetic Neuropathic Pain Drug Sales by Country (2027-2032)
  6. 7.4 Global Diabetic Neuropathic Pain Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Diabetic Neuropathic Pain Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Diabetic Neuropathic Pain Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Diabetic Neuropathic Pain Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Diabetic Neuropathic Pain Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Diabetic Neuropathic Pain Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Company
  2. 8.1.1 Eli Lilly and Company Company Information
  3. 8.1.2 Eli Lilly and Company Business Overview
  4. 8.1.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio
  6. 8.1.5 Eli Lilly and Company Recent Developments
  7. 8.2 Astellas Pharma Inc.
  8. 8.2.1 Astellas Pharma Inc. Company Information
  9. 8.2.2 Astellas Pharma Inc. Business Overview
  10. 8.2.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  12. 8.2.5 Astellas Pharma Inc. Recent Developments
  13. 8.3 AstraZeneca Plc
  14. 8.3.1 AstraZeneca Plc Company Information
  15. 8.3.2 AstraZeneca Plc Business Overview
  16. 8.3.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio
  18. 8.3.5 AstraZeneca Plc Recent Developments
  19. 8.4 Theravasc, Inc.
  20. 8.4.1 Theravasc, Inc. Company Information
  21. 8.4.2 Theravasc, Inc. Business Overview
  22. 8.4.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  24. 8.4.5 Theravasc, Inc. Recent Developments
  25. 8.5 Sphaera Pharma Pvt. Ltd.
  26. 8.5.1 Sphaera Pharma Pvt. Ltd. Company Information
  27. 8.5.2 Sphaera Pharma Pvt. Ltd. Business Overview
  28. 8.5.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
  30. 8.5.5 Sphaera Pharma Pvt. Ltd. Recent Developments
  31. 8.6 Relmada Therapeutics, Inc.
  32. 8.6.1 Relmada Therapeutics, Inc. Company Information
  33. 8.6.2 Relmada Therapeutics, Inc. Business Overview
  34. 8.6.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  36. 8.6.5 Relmada Therapeutics, Inc. Recent Developments
  37. 8.7 RAPID Pharmaceuticals AG
  38. 8.7.1 RAPID Pharmaceuticals AG Company Information
  39. 8.7.2 RAPID Pharmaceuticals AG Business Overview
  40. 8.7.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio
  42. 8.7.5 RAPID Pharmaceuticals AG Recent Developments
  43. 8.8 Pharmaleads
  44. 8.8.1 Pharmaleads Company Information
  45. 8.8.2 Pharmaleads Business Overview
  46. 8.8.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio
  48. 8.8.5 Pharmaleads Recent Developments
  49. 8.9 Novaremed
  50. 8.9.1 Novaremed Company Information
  51. 8.9.2 Novaremed Business Overview
  52. 8.9.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novaremed Diabetic Neuropathic Pain Drug Product Portfolio
  54. 8.9.5 Novaremed Recent Developments
  55. 8.10 Mertiva AB
  56. 8.10.1 Mertiva AB Company Information
  57. 8.10.2 Mertiva AB Business Overview
  58. 8.10.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio
  60. 8.10.5 Mertiva AB Recent Developments
  61. 8.11 Lohocla Research Corporation
  62. 8.11.1 Lohocla Research Corporation Company Information
  63. 8.11.2 Lohocla Research Corporation Business Overview
  64. 8.11.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio
  66. 8.11.5 Lohocla Research Corporation Recent Developments
  67. 8.12 Laboratorios Del Dr. Esteve S.A.
  68. 8.12.1 Laboratorios Del Dr. Esteve S.A. Company Information
  69. 8.12.2 Laboratorios Del Dr. Esteve S.A. Business Overview
  70. 8.12.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio
  72. 8.12.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
  73. 8.13 Immune Pharmaceuticals Inc.
  74. 8.13.1 Immune Pharmaceuticals Inc. Company Information
  75. 8.13.2 Immune Pharmaceuticals Inc. Business Overview
  76. 8.13.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  78. 8.13.5 Immune Pharmaceuticals Inc. Recent Developments
  79. 8.14 Hydra Biosciences, Inc.
  80. 8.14.1 Hydra Biosciences, Inc. Company Information
  81. 8.14.2 Hydra Biosciences, Inc. Business Overview
  82. 8.14.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  84. 8.14.5 Hydra Biosciences, Inc. Recent Developments
  85. 8.15 Glenmark Pharmaceuticals Ltd.
  86. 8.15.1 Glenmark Pharmaceuticals Ltd. Company Information
  87. 8.15.2 Glenmark Pharmaceuticals Ltd. Business Overview
  88. 8.15.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
  90. 8.15.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  91. 8.16 Dong-A Socio Group
  92. 8.16.1 Dong-A Socio Group Company Information
  93. 8.16.2 Dong-A Socio Group Business Overview
  94. 8.16.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio
  96. 8.16.5 Dong-A Socio Group Recent Developments
  97. 8.17 Daiichi Sankyo Company, Limited
  98. 8.17.1 Daiichi Sankyo Company, Limited Company Information
  99. 8.17.2 Daiichi Sankyo Company, Limited Business Overview
  100. 8.17.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio
  102. 8.17.5 Daiichi Sankyo Company, Limited Recent Developments
  103. 8.18 Boehringer Ingelheim GmbH
  104. 8.18.1 Boehringer Ingelheim GmbH Company Information
  105. 8.18.2 Boehringer Ingelheim GmbH Business Overview
  106. 8.18.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio
  108. 8.18.5 Boehringer Ingelheim GmbH Recent Developments
  109. 8.19 BioDelivery Sciences International, Inc.
  110. 8.19.1 BioDelivery Sciences International, Inc. Company Information
  111. 8.19.2 BioDelivery Sciences International, Inc. Business Overview
  112. 8.19.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  114. 8.19.5 BioDelivery Sciences International, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Diabetic Neuropathic Pain Drug Value Chain Analysis
  2. 9.1.1 Diabetic Neuropathic Pain Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Diabetic Neuropathic Pain Drug Sales Mode & Process
  6. 9.2 Diabetic Neuropathic Pain Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Diabetic Neuropathic Pain Drug Distributors
  9. 9.2.3 Diabetic Neuropathic Pain Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst